NCT07374302Not yet recruiting
Riociguat in Triple Therapy for Pulmonary Arterial Hypertension in Real-World Practice
REAPPRAISED: Riociguat in Triple Therapy for Pulmonary Arterial Hypertension - A Single-Center Retrospective Study With Composite Endpoint Evaluation
Source: ClinicalTrials.gov · Last updated 28 Jan 2026
Brief summary (registry, in English)
Pulmonary arterial hypertension is a rare and serious disease that can lead to heart failure and early death despite modern treatments. Many patients are treated with a combination of medications targeting different disease pathways, but some continue to have an inadequate response. Riociguat is a medication that acts on the nitric oxide pathway and may be beneficial in patients who do not respond well to phosphodiesterase-5 inhibitors. In routine clinical practice, some patients receiving triple therapy switch from a phosphodiesterase-5 inhibitor to riociguat. The REAPPRAISED study evaluates outcomes in patients with pulmonary arterial hypertension who switched to riociguat while receiving triple therapy. This observational study uses data from routine clinical care and does not involve any experimental treatment. The results may help improve understanding of the effectiveness and safety of this treatment strategy in real-world practice.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 15 (estimated)
- First submitted
- 12 Jan 2026
- Start date
- 1 Mar 2026
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Caio Júlio César dos Santos Fernandes
- NCT number
- NCT07374302
What you commit to
- Study type: Observational
- Planned participants: 15
- From 1 Mar 2026 to the primary completion date, 31 Dec 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concomitant use of phosphodiesterase-5 inhibitors and riociguat.
Other
- Inability to confirm vital status or hospitalization outcomes within 6 months.
- Participation in an interventional clinical trial that mandated the treatment switch.
Who the study is looking for
- Adults aged 18 years or older.
- Confirmed diagnosis of pulmonary arterial hypertension (Group 1).
- Treatment with triple therapy including an endothelin receptor antagonist, a prostacyclin pathway agent, and a phosphodiesterase-5 inhibitor for at least 12 weeks.
- Switch from a phosphodiesterase-5 inhibitor to riociguat as part of routine clinical care.
- Availability of minimum data to assess the primary outcome at 6 months.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.